About This Course

Welcome to this 30-minute e-learning course created for physicians and physician assistants. After completing this course, physicians will improve their knowledge of biosimilar G-CSFs in treatment of chemotherapy-induced neutropenia. They will become better skilled in detecting patients who are at risk for neutropenia and its complications. They will be prepared to educate their patients about how neutropenia influences their treatment pathway. Clinicians will learn how G-CSFs are used prophylactically and in the management of the condition. They will understand how biosimilars are developed and used to achieve the same outcomes for patients as their reference products. Getting an overview of the current laws, economic, and practical considerations when incorporating a biosimilar into the formulary, the clinicians will be equipped in switching patients to a biosimilar.


CME/CPD Information

This course is accredited by the Accreditation Council for Continuing Medical Education (ACCME) with 0.5 AMA PRA Category 1 Credits™.

To claim your credit, you will need to complete the course and the final quiz on the MyCME platform.
Follow this link to claim your credit: 

Biosimilars in Chemotherapy Induced Neutropenia | myCME 


Launch date: 22nd January 2024
Expiry date:  22nd January 2025

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert AMA PRA Category 1 Credits™ to an equivalent number of  EACCME® credits. Information on the process to convert AMA credits to EACCME credits can be found at Agreement with European Union of Medical Specialties (UEMS) | American Medical Association (ama-assn.org).

Learning Outcomes

By the end of this course, you should be able to:

  • Detect febrile neutropenia in patients receiving chemotherapy.

  • Educate patients about febrile neutropenia and tracking of early symptoms of infection.

  • List chemotherapy regimens that significantly increase the risk of febrile neutropenia.

  • Assess the risk of patients developing febrile neutropenia and explain how this influences their treatment pathway.

  • Describe how G-CSFs are used prophylactically and in the management of chemotherapy-induced neutropenia.

  • Explain how biosimilars are developed and used to achieve the same outcomes for patients as their reference products.

  • State the use cases of biosimilars in oncology supportive care.

  • List clinical and economic considerations, and know the current laws, when incorporating a biosimilar into the formulary.

Expert Faculty

This course has been made in close collaboration with:

Course curriculum

    1. Welcome to the Course

    1. Introduction to Precourse Quiz

    2. Precourse Quiz

    1. About Chemotherapy-Induced Neutropenia

    1. Long-Acting G-CSFs in Prophylaxis and Management

    1. Biosimilars' Role in Prevention, Management, and Access

    1. Introduction to Final Quiz

    2. Final Quiz

    1. Summary Sheet

    2. Course Feedback Survey

About this course

  • Free
  • 10 lessons
  • 0 hours of video content

This activity is supported by an educational grant from FRESENIUS KABI BIOPHARMA.

Certificate
Multimedia
PDF
Text
Survey
Quiz
FREE
Enroll course